- |||||||||| Opdivo (nivolumab) / BMS, Stivarga (regorafenib) / Bayer, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Metastases: Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 5, 2024
P1, N=39, Active, not recruiting,
A diagnosis of ocrelizumab-induced autoimmune colitis was made. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Microsatellite instability, BRCA Biomarker, PD(L)-1 Biomarker: Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation. (Pubmed Central) - Aug 5, 2024
Metastatic hormone-sensitive prostate cancer (mHSPC) often has an abbreviated, aggressive disease course, and can have varying presentations with different molecular profiles that determine response/resistance to the approved treatments targeting the androgen-receptor pathway (eg, enzalutamide, apalutamide, darolutamide, and abiraterone acetate). We present a case of mHSPC quickly progressing to mCRPC, found to have microsatellite instability in mCRPC and excellent response to pembrolizumab, which raises the critical issues of early molecular testing and treatments personalized for the individual patient.
- |||||||||| Kimmtrak (tebentafusp-tebn) / Immunocore
Journal: Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment. (Pubmed Central) - Aug 5, 2024
Despite tebentafusp has demonstrated promising results in the treatment of uveal melanoma, the number of patients to benefit from this new approach can strongly vary by ethnic and racial issues. New strategies for the systemic treatment of advanced uveal melanoma have to be developed and tested as this disease still represents an unmet medical need.
- |||||||||| Opdivo (nivolumab) / BMS
Journal, Tumor cell: Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients. (Pubmed Central) - Aug 5, 2024
We find a resistance mechanism signature in one fifth of glioblastoma patients associated with a tumor-cell transition to a more aggressive mesenchymal-like state, increase in TAMs and proliferative and exhausted T cells in response to immunotherapy. These patients may instead benefit from neuro-oncology therapies targeting mesenchymal tumor cells.
- |||||||||| Rituxan (rituximab) / Roche
Neonatal pemphigus a bullous dermatosis of infants (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4590;
In conclusion, neonatal pemphigus is a benign pathology, with a favorable evolution in the absence of treatment. It should be noted, however, that although a biopsy officially determines the disease, in this case it was not necessary, due to the maternal history and satisfactory clinical evolution during the patient
- |||||||||| Outcomes in resected stage III/IV melanoma patients treated with adjuvant targeted therapy or anti-PD1 agents: a four-year analysis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4393;
Overall, the proportion of BRAF-mutated patients receiving IT stood at 7.4%, notably lower than what was observed in clinical trials, confirming the trend to administer adjuvant TT to this subset of patients in Italy. These results confirm the real-life effectiveness and safety of adjuvant regimens yet underscore the need for further research to explore biomarker-based predictors for relapse and to assess the translation of improved RFS into long-term OS benefit.
- |||||||||| colchicine / Generic mfg.
Two cases of the successful use of colchicine in treating recalcitrant epidermolysis bullosa acquisita. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4318;
It presents in inflammatory and mechanical-bullous forms with diverse clinical phenotypes. Differential diagnosis relies on histopathological examination and direct immunofluorescence, demonstrating characteristic features such as subepidermal blisters and linear IgG and C3 deposition along the basement membrane zone.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Early serum markers for Immune checkpoint inhibitor induced hypophysitis in melanoma patients (Open Stage) - Aug 5, 2024 - Abstract #EADV2024EADV_4290;
This research emphasizes the need for regular monitoring of T4 hormone levels, while TSH monitoring proved beneficial primarily in patients treated with ipilimumab-based ICI regimens. Hyponatremia was commonly observed in patients with immune-related hypophysitis, suggesting that it could serve as an indicator for further evaluations, including tests for ACTH and cortisol levels.
- |||||||||| tofacitinib / Generic mfg.
Recalcitrant and widespread granuloma annulare successfully managed with tofacitinib (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4239;
Over the initial treatment period of four years, the interventions listed below offered little or no benefit: doxycycline, PUVA, doxepin, topical corticosteroids, hydroxychloroquine, tacrolimus 0.1% ointment, acitretin, mepacrine, ciclosporin, dapsone, pentoxifylline, hydroxycarbamide, fumaric acid esters, methotrexate, potassium iodide, rituximab, isotretinoin and mycophenolate mofetil. Upon treatment with infliximab, she showed promising improvement in her GA...This resulted in major impact on patient
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
A Case of Paraneoplastic Granuloma Annulare in a Patient with Breast Cancer: An Atypical Presentation (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4228;
Materials & A 47-year-old woman was admitted for neutropenic sepsis (on meropenem,previously on tazocin) and was referred to our acute dermatology on call with an 8-day history of erythematous rash on the hands, forearms, trunk, and lower limbs...She had completed neoadjuvant chemotherapy and immunotherapy (paclitaxel, carboplatin, and pembrolizumab) , and she was on epirubicin and cyclophosphamide... A rare association of granuloma annulare (GA) with breast cancer exists, and in a patient with suspected or confirmed malignancy who presents with an acute or refractory cutaneous eruption, early biopsy should be used to rule out rare cutaneous involvement due to underlying disease.
- |||||||||| Rinvoq (upadacitinib) / AbbVie, Rituxan (rituximab) / Roche
disseminated cutaneous-only histoplasmosis in two immunosupressed patients (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4051;
In a booming era of immunosuppressive treatments and biologics, we present two cases of disseminatedcutaneous-only histoplasmosis which is an uncommon clinical form observed in two argentinianimmunosuppressed patients.A 73-year-old female patient with history of dermatomyositis, immunosuppressed with methylprednisolone,azathioprine, rituximab and mycophenolate mofetil who arrived at our dermatology ward with poor generalcondition and consulted for four months old painful skin ulcers on her face and the upper limbs associated withweight loss, denying respiratory symptoms and fever...She underwent treatment with intravenous Amphotericin B for 2 week and later with daily oralitraconazole showing clinical improvement of skin lesions.The second case is a 36-year-old female patient with a history of an Asia Syndrome with joint involvement,multiple mononeuritis, dysautonomia, hyperreflexic neurogenic bladder, and gastroparesis undergoing treatmentwith upadacitinib, mycophenolate, long-term corticosteroids who consulted for two-week-old painful erythematoviolaceous, edematous, and infiltrated plaque covered by some crusts in the infraumbilical region.A soft tissue ultrasound was requested, which showed an increased echogenicity of the adipose tissue at thesubcutaneous level, without evidence of collections or communication...A positive PCR for Histoplasma capsulatum was also obtained from skin biopsy, establishing thediagnosis of disseminated histoplasmosis with dermal involvement. Complementary studies had no significantalterations.In light of these findings, immunosuppressive treatment was discontinued and she underwent the same antifungaltreatment with a good clinical response.
- |||||||||| Rituxan (rituximab) / Roche
Experience of managing a patient with blastomycosis (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3908;
From the anamnesis it is known that the man came from Jordan 2 years ago, after he was subsequently diagnosed with diffuse large cell lymphoma, and therefore received 4 courses of RCHOP chemotherapy...The treatment included desensitizing infusion therapy with hepatoprotectors and antihistamines, antibiotic therapy (doxycycline 100 mg 2 times a day 20 days) , and antifungal therapy (nystatin 500 mg 3 times a day, 30 days, terbinafine 250 mg 2 times a day, 20 days)... thus, blastomycosis is a rare disease from the group of deep mycoses, usually found in immunocompromised patients and in late stages leads to damage to internal organs, as well as the nervous system.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Multiple patterns of cutaneous metastases of malignant melanoma in a single patient (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3494;
Dermoscopic findings of CMMM can be challenging to interpret, particularly in patients with multiple atypical nevi. Dermoscopy should always be included as a mandatory step in the follow-up schedule of melanoma patients, allowing for the early diagnosis of CMMM that could change their treatment and prognosis.
- |||||||||| Rituxan (rituximab) / Roche
Eosinophilic fasciitis: a two case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3343;
These cases underscore the diagnostic challenges of eosinophilic fasciitis, often mistaken for scleroderma, delaying appropriate management. Rapid, generalized progression sparing the face and hands, along with the absence of Raynaud
- |||||||||| Rituxan (rituximab) / Roche
Cutaneous Manifestation Predictive of Progression and Poor Prognosis in Non-Hodgkin Lymphoma: A Case Report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3308;
She had been undergoing chemotherapy for B-cell large cell lymphoma exclusively involving the lymph nodes, having completed sessions with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, with the last session less than 6 months ago...It was then decided to restart treatment with dexamethasone, cytarabine, and cisplatin...There are several reports in the literature whit skin involvement by lymphoma. Most of these cases however describe the skin as the disease
- |||||||||| Rituxan (rituximab) / Roche
Extensive Secondary Cutaneous Involvement in Systemic Diffuse Large B Cell Lymphoma (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3241;
Systemic steroids stand out as the most effective treatment for SS. He was diagnosed six months prior and was treated with six cycles of R-CHOP, achieving a complete response...In conclusion, we report a unique case of disseminated secondary cutaneous DLBCL, highlighting the importance of timely diagnosis and management in such presentations.
- |||||||||| Rituxan (rituximab) / Roche
Cutaneous large B-cell lymphoma, EBV (+): on the scalp (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3156;
Extension studies are requested without evidence of systemic disease. He is referred to the hematology service where he receives 5 cycles of R-Chop with satisfactory progress.
- |||||||||| Orencia (abatacept) / BMS
Progressive polycranial neuropathy as the presenting symptom of metastatic cutaneous squamous cell carcinoma (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3153;
Introduction & Objectives: Case report A 64-year-old man was attending the dermatology department for morphea, managed with abatacept, which he had been stable on for over five years...Patients should be treated aggressively with surgery and/or radiotherapy for optimal outcomes. Immunotherapy can be used for advanced or metastatic cSCC (3) .
- |||||||||| Campath (alemtuzumab) / Sanofi
Atypical acne: diagnostic trap!!! (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3127;
Inadequate response is an indication for aggressive systemic treatment: mono (chemo) - therapies: gemcitabine, liposomal doxorubicin, or alemtuzumab... The originality of our case is the long diagnostic delay which is not linked to the patient but to a delay in carrying out a skin biopsy due to the atypical clinical appearance and the lack of knowledge of this rare entity by clinicians.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Early Serum Markers for Immune Checkpoint inhibitor induced Hypophysitis in Melanoma Patients (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3108;
This research emphasizes the need for regular monitoring of T4 hormone levels, while TSH monitoring proved beneficial primarily in patients treated with ipilimumab-based ICI regimens. Hyponatremia was commonly observed in patients with immune-related hypophysitis, suggesting that it could serve as an indicator for further evaluations, including tests for ACTH and cortisol levels.
- |||||||||| Rituxan (rituximab) / Roche
An Aggressive B-Cell Lymphoma Revealed: High-Grade Large B-Cell Lymphoma in a 16-Year-Old Girl. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3100;
Hyponatremia was commonly observed in patients with immune-related hypophysitis, suggesting that it could serve as an indicator for further evaluations, including tests for ACTH and cortisol levels. The treatment of choice is the combination of Rituximab and CHOP chemotherapy (5), which our patient received; the prognosis appears to be better than that of T-cell lymphomas(6).
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Revealing the Phenomenon of Nevi Regression in a Patient with Multiple Primary Melanomas (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3096;
The observed regression, possibly triggered by the most recent primary melanoma, underscores the immunostimulatory potential of melanoma progression, similarly to the commonly discussed melanoma-associated vitiligo. Further research on the immunological dynamics driving nevus regression and melanoma pathogenesis is needed to elucidate this rare phenomenon.
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
A 100-year-old patient with inoperable squamous cell carcinoma (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3093;
Determining if the carcinoma is low-risk, high-risk, locally advanced, if there are regional or distant metastases, is important for the final decision - whether the tumour is operable or not. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC.
- |||||||||| Campath (alemtuzumab) / Sanofi, Adcetris (brentuximab vedotin) / Takeda, Pfizer, Leukeran (chlorambucil) / GSK
Granulomatous Slack Skin: An Unusual Variant of Mycosis Fungoides (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3086;
Multidisciplinary board decisions are mandatory for all patients with advanced cSCC. Considering the patient
- |||||||||| Bavencio (avelumab) / EMD Serono
Merkel cell cancer: the need to standardize care (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3082;
This audit suggests that MCC is a poorly recognised cancer with tumours presenting mostly in older and frail people for whom invasive staging and surgery appears less acceptable. This audit highlights the need for better recognition of the cancer and a standardised approach to patient care.
- |||||||||| Opdivo (nivolumab) / BMS
Melanoma metastases to the scalp : A case series (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3061;
Melanomas with metastases to the scalp are associated with poor outcomes. Further studies are needed to evaluate patients who are at higher risk of developing metastases to the scalp and develop more efficacious treatments.
- |||||||||| Kisqali (ribociclib) / Novartis
Massive cutaneous metastasis from breast cancer, an unusual clinical presentation. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3048;
In conclusion, skin metastasis of breast cancer represents a complex clinical entity that requires comprehensive evaluation and individualized management strategies. Early recognition of cutaneous manifestations, prompt diagnostic workup, and timely initiation of appropriate treatment modalities are crucial for optimizing patient outcomes.
- |||||||||| Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Targretin oral (bexarotene oral) / ReXceptor, Adcetris (brentuximab vedotin) / Takeda, Pfizer
The rare type of mycosis fungoides - case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3046;
After diagnostic examination and diagnosis of T cell lymphoma MF folliculotropic type, the patient was referred to the Center for Hematology, where combination chemotherapy of cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone (CHOEP) was administered, with predicted VI cycles. When treatments are timely and carried out in the less advanced stages of the disease, the progression of mycosis fungoides can be stopped, entering the remission when the clinical manifestations of the disease disappear.
- |||||||||| Rituxan (rituximab) / Roche
Cutaneous B lymphoma with rapid regression: case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3044;
Over half of all cutaneous B-cell lymphomas are primary cutaneous lymphomas of the follicular center. This is a low-grade lymphoma that develops over months or years without spontaneous regression.
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
Male breast cancer masked with herpes zoster (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3039;
Physicians should be aware of male breast cancer in male patients with a painless breast mass. It should be noted that additional inflammatory diseases may mask breast cancer nodules.
- |||||||||| Elzonris (tagraxofusp-erzs) / Menarini
Blastic Plasmocytoid dendritic cell neoplasm and Down Syndrome (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3024;
The prognosis is poor, with a median survival of 8 to 16 months, and treatment is complex, characterized by resistance to standard chemotherapy. Treatment options are hyperCVAD and CHOP, which are therapeutic options for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Lymphoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Metastatic pediatric melanoma: two exceptional and challenging case reports (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2997;
Clinicians should be vigilant and consider melanoma even in lesions clinically suggestive of benign conditions. Emphasizing histological scrutiny and tailored therapeutic strategies is crucial for navigating complexities associated with paediatric melanoma, influencing patient outcomes.
|
